Literature DB >> 6170256

Combined protective effects on interferon and interferon induction on herpes simplex and ectromelia virus infections in mice.

J Imanishi, M Matsubara, C J Won, H Nomura, T Kishida.   

Abstract

Mouse interferon or the induction of mouse interferon with polyriboinosinic acid-polyribocytidylic acid significantly protected mice against herpes simplex and ectromelia viral infections. When polyriboinosinic acid-polyribocytidylic acid was administered 24 h before herpes simplex or ectromelia viral infection and mouse interferon was administered shortly before and 24 h after infection, a combined protective effect against either herpes simplex or ectromelia viral infection in mice was evident. There was a significant decrease in the mortality rate with the combined treatment as compared either with the rate in group treated with interferon or polyriboinosinic acid-polyribocytidylic acid.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6170256      PMCID： PMC181543          DOI： 10.1128/AAC.19.5.922

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Clinical trials with exogenous interferon: summary of a meeting.

Authors:  J K Dunnick; G J Galasso
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

2.  Large-scale production of human leukocyte interferon containing 10(8) units per ml.

Authors:  K Cantell; S Hirvonen
Journal:  J Gen Virol       Date:  1978-06       Impact factor: 3.891

3.  Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer.

Authors:  A S Levine; M Sivulich; P H Wiernik; H B Levy
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

4.  Large-scale production and concentration of human lymphoid interferon.

Authors:  F Klein; R T Ricketts; W I Jones; I A DeArmon; M J Temple; K C Zoon; P J Bridgen
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

5.  Synergy of 9-beta-D-arabinofuranosyladenine and human interferon against Herpes simplex virus, type 1.

Authors:  A M Lerner; E J Bailey
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

6.  Interferon appearance stimulated by endotoxin, bacteria, or viruses in mice pre-treated with Escherichia coli endotoxin or infected with Mycobacterium tuberculosis.

Authors:  J S Youngner; W R Stinebring
Journal:  Nature       Date:  1965-10-30       Impact factor: 49.962

7.  Enhancement of antiviral protection against encephalomyocarditis virus by a combination of isoprinosine and interferon.

Authors:  C Chany; I Cerutti
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

8.  Effect of ammonium 5-tungsto-2-antimoniate on encephalomyocarditis and vesicular stomatitis virus infections in mice.

Authors:  G H Werner; C Jasmin; J C Chermann
Journal:  J Gen Virol       Date:  1976-04       Impact factor: 3.891

9.  Differential sensitivity of herpes simplex virus types 1 and 2 to human interferon: antiviral effects of interferon plus 9-beta-D-arabinofuranosyladenine.

Authors:  A M Lerner; E J Bailey
Journal:  J Infect Dis       Date:  1976-10       Impact factor: 5.226

10.  Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans.

Authors:  K J Champney; D P Levine; H B Levy; A M Lerner
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441
  10 in total
  2 in total

1.  Protective effect of exogenous recombinant mouse interferon-gamma and tumour necrosis factor-alpha on ectromelia virus infection in susceptible BALB/c mice.

Authors:  A V Atrasheuskaya; E K Bukin; T M Fredeking; G M Ignatyev
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 2.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.